ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1634

Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments?

Therese Posas-Mendoza1, Cara McLeod1, William Davis2 and Robert Quinet2, 1Ochsner Medical Center, New Orleans, LA, 2Dept of Rheumatology, Ochsner Medical Center, New Orleans, LA

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, cytokines, Juvenile idiopathic arthritis, macrophage activation syndrome, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster III: Therapies

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a rare life-threatening disease characterized by immune-overstimulation and a hyperinflammatory response resulting in cytokine storm and multi-organ failure.1 Secondary HLH usually occurs in adults in the setting of malignancy, infection, or a rheumatic condition. It is often triggered by an infection such as Epstein-Barr virus (EBV).1 Secondary HLH occurring in patients with autoimmune diseases is referred to as macrophage activation syndrome (MAS). The approach to the management of secondary HLH can be confusing and problematic due to the rarity of the condition and the heterogeneity of treatment approaches for HLH. The aim of this study was to study the patients diagnosed with hemophagocytic lymphohistiocytosis at our center, and to compare their predisposing conditions, treatments, and outcomes.

Methods: We conducted a retrospective chart review of all patients over 18 years of age diagnosed with hemophagocytic lymphohistiocytosis at our center between 2013 and 2019. Patients who met HLH-2004  or H-score criteria were included in this study. The patients’ presentations, management, and outcomes were analyzed. 

Results: Twenty-nine patients with hemophagocytic lymphohistiocytosis met inclusion criteria. 7 patients had a malignancy, 11 had a rheumatic disease, 6 had an infection alone, 2 were transplant patients, and 3 had a combination of malignancy, rheumatic disease, and/or infection. Of all the patients treated with the HLH-94 protocol 73% (11/15) died, 13% (2/15) had recurrence of HLH, and 6% (1/15) developed an invasive fungal infection. The patients with underlying rheumatologic conditions received targeted personalized therapy with pulse steroids, tocilizumab, anakinra, IVIg, cyclosporin, rituximab and/or cyclophosphamide in addition to antiviral/antibiotic therapy. All of the patients treated with targeted therapy had resolution of HLH.

Conclusion: Our findings suggest that the rheumatologic patient population responds well to a targeted and more personalized therapeutic approach, and poorly to the standard HLH-94 protocol. It is unclear whether the poor outcomes found with the use of the HLH protocol are secondary to the protocol itself, or the aggressive nature of malignancy-associated HLH. HLH is a rare life-threatening disease, and further studies are needed to develop more tailored therapeutic regimens.

Table 1: Therapeutic Approaches and Outcomes (1/2)

Table 1: Therapeutic Approaches and Outcomes (2/2)


Disclosure: T. Posas-Mendoza, None; C. McLeod, None; W. Davis, None; R. Quinet, None.

To cite this abstract in AMA style:

Posas-Mendoza T, McLeod C, Davis W, Quinet R. Etiologies and Management of Hemophagocytic Lymphohistiocytosis: Is It Time for an Updated Protocol and Targeted Treatments? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/etiologies-and-management-of-hemophagocytic-lymphohistiocytosis-is-it-time-for-an-updated-protocol-and-targeted-treatments/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/etiologies-and-management-of-hemophagocytic-lymphohistiocytosis-is-it-time-for-an-updated-protocol-and-targeted-treatments/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology